(MENAFN- Andrew Lloyd & Associates)
The two entities strengthen their partnership to support, develop and finance the most innovative European startups in the field of life sciences
Paris, France, May 3, 2022 – AdBio Partners, an AMF-regulated investment company dedicated to life sciences, and Inserm Transfert, the private subsidiary of the National Institute for health and Medical Research (Inserm ) focused on technology transfer in the life sciences and the promotion of Inserm innovations, announce today that Inserm Transfert has joined the investors of the second fund of AdBio partners - AFB Fund II.
“We are delighted to welcome Inserm Transfert as an investor in our second fund. It is a prestigious partner of the French and European life sciences industry.We share the same vision: to promote entrepreneurship in French academic health research and contribute to the development of an ecosystem that is sometimes compartmentalized but also rich in innovation and talent. This is the objective that we will pursue together,” said Alain Huriez, Chairman and CEO of AdBio Partners.
This partnership will facilitate the start-up and the search for funding for the most innovative start-ups in the life sciences, while strengthening the entrepreneurial skills of scientists from academic research, such as those from Inserm. AdBio's partner portfolio already contains a number of companies whose IP comes from Inserm, such as Alderaan Biotechnology, DiogenX,This is a clear demonstration of the work already undertaken by the two partners in recent years.
“We know AdBio's team of partners well, their network and their experience as investors-entrepreneurs in early-stage healthcare companies. This combination of factors has convinced us that it is the ideal partner to strengthen the role of entrepreneurship in our value creation strategy, as we seek concrete ways to bring innovative technologies to market for the benefit of everyone," added Pascale Augé, President. of the Executive Board of Inserm Transfert.
Inserm Transfert joins the international sponsors who have invested in AdBio Partners' second fund. The first closure announced in September 2021 reaches 86 million euros ($102 million). These other investors include the European Investment Fund (EIF), the French Seed Fund 2 (FNA 2), managed by Bpifrance on behalf of the French State as part of the future investment program, Boehringer Ingelheim Venture Fund, Pierre Fabre, various family office funds and the management of AdBio partners.
“It is crucial that we continue to develop early stage financing for new businesses in France and in Europe. AdBio partners has put together a team of experts to take up this challenge and create start-ups in direct partnership with the scientists and academic researchers behind the innovations;Inserm is a major French player in this sector,” explains Matthieu Coutet, managing partner at AdBio partners.
Inserm Transfert has helped Inserm startups raise more than 1.66 billion euros ($1.78 billion) since 2010. About ten startups are created each year from innovations researched by Inserm .
About Inserm Transfert
Inserm Transfert, a private subsidiary of the National Institute for Health and Medical Research (Inserm), is responsible for creating value from the innovations of Inserm and its academic partners in human health , and promotes long-term technology transfers in line with the best international standards. practices.Inserm Transfert SA was created in 2000. It manages, within the framework of a Public Service Management Contract (Public Service Delegation), all of the development and transfer of knowledge from the research laboratories of the Inserm to the industrial world, from invention disclosure to industrial partnerships and start-up incorporation. Inserm Transfert also offers services relating to the setting up and management of national, European and international projects, as well as support for the technology transfer of clinical research and health data/databases. In 2009, Inserm Transfert and Inserm created an investment fund to finance proofs of concept.In 2005, Inserm Transfert Initiative, a seed fund dedicated to life sciences, was created. Since 2017, a pre-entrepreneurship course has been supporting researchers/inventors who aspire to engage in entrepreneurship.
About AdBio partners
AdBio partners (formerly Advent France Biotechnology) is an AMF-regulated company that invests in various life science sectors, particularly in therapeutic projects.
AdBio's unique partner strategy combines seed investments in promising companies and strong entrepreneurial support to enhance business growth.
Created in 2016, AdBio partners has made 17 European investments in France, Belgium, Spain and Ireland.
AdBio partners have developed strong relationships within the European innovation ecosystem; as a result, he attracted international venture capital syndicates to his portfolio companies.
The operational team is led by Alain Huriez and Matthieu Coutet. He appointed a number of investment professionals with long experience in entrepreneurial ventures, combined with strong scientific and medical expertise.
MENAFN09052022006205013440ID1104181093
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.